CoChat

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

Open access

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. OBJECTIVE: We aimed to evaluate the characteristics and clinical outcomes of patients who received their first treatment for metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used, including subgroups with baseline cardiac disease, diabetes mellitus, or visceral metastases. PATIENTS AND METHODS: Prospective, noninterventional analysis of patient record data in the multicenter Prostate Cancer Registry (PCR) of men with mCRPC. The data were collected in 16 countries with the aim of recruiting more than 3000 patients between 2013 and 2016. The study end date was 9 July 2018. Data evaluated included baseline characteristics, treatment exposure, and efficacy outcomes [overall survival (OS) and time to progression (TTP)] of patients treated with abiraterone acetate plus prednisone or prednisolone (collectively, "abiraterone"), enzalutamide, or docetaxel. Descriptive outcomes are reported from the overall patient population and subgroups of patients with baseline cardiovascular disease, diabetes mellitus, or visceral metastases. The treatment effects for time to progression were compared for the overall patient population. RESULTS: The study enrollment period lasted 2.5 years, and each patient was followed for a maximum of 3 years. A total of 1874 patients in the PCR had not received previous mCRPC treatment at baseline, although they had received androgen-deprivation therapy. Prevalent co-morbidities included cardiovascular disease in 65.4% and diabetes mellitus in 17.4% of patients. Baseline characteristics suggested that patients with more advanced disease received docetaxel treatment. In the overall patient population, the median time to progression with abiraterone, enzalutamide, and docetaxel as first-line mCRPC therapy was 9.6, 10.3, and 7.6 months, respectively, and median OS was 27.1, 27.1, and 27.9 months, respectively. Outcomes in the subgroups of patients with cardiovascular disease or diabetes mellitus were similar to those of the whole population in the analysis. As expected, patients with visceral metastases had shorter TTP and OS than patients in the overall population. CONCLUSIONS: This analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in patients with visceral metastases. These real-world findings from the PCR provide meaningful information to help manage mCRPC, particularly in patients under-represented in clinical studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02236637; registered September 2014.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11523-020-00720-2

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Time to progression in the first-line treatment population (a), and cardiovascular (b), diabetes mellitus (c), and visceral metastases subgroups (d). Abi abiraterone, Enz enzalutamide, Doc docetaxel
Fig. 1 Time to progression in the first-line treatment population (a), and cardiovascular (b), diabetes mellitus (c), and visceral metastases subgroups (d). Abi abiraterone, Enz enzalutamide, Doc docetaxelCC BY-NC · PubMed Central
Fig. 2 Overall survival in the first-line treatment population (a), and cardiovascular (b), diabetes mellitus (c), and visceral metastases subgroups (d). Abi abiraterone, Enz enzalutamide, Doc docetaxel
Fig. 2 Overall survival in the first-line treatment population (a), and cardiovascular (b), diabetes mellitus (c), and visceral metastases subgroups (d). Abi abiraterone, Enz enzalutamide, Doc docetaxelCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 93

Metadata

Authors
Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., Feyerabend, S., Matveev, V., Lefresne, F., Lukac, M., Wapenaar, R., & Costa, L.
Affiliations
  • Sarah Cannon Research Institute (GB)
  • Skåne University Hospital (SE)
  • Ghent University Hospital (BE)
  • Universitat Autònoma de Barcelona (ES)
  • Royal Preston Hospital (GB)
  • Medical University of Vienna (AT)
  • Praxis für Humangenetik Tübingen (DE)
  • Russian Cancer Research Center NN Blokhin (RU)
  • Janssen (Belgium) (BE)
Corresponding author
Chowdhury, Simon
Venue
Targeted Oncology
Published
2020-06
Volume
15
Issue
3
Pages
301-315
ISSN
  • 1776-2596 (ISSN-L)
  • 1776-260X
OpenAlex
W3033684926
Cited by
86
References
11
Citations by year
2026: 15 · 2025: 14 · 2024: 18 · 2023: 10 · 2022: 13 · 2021: 14 · 2020: 2
FWCI
5.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Targeted Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
Janssen EMEA
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
metastatic castration-resistant prostate cancer, first-line therapy, abiraterone, enzalutamide, docetaxel, overall survival, time to progression, cardiovascular disease, diabetes mellitus, visceral metastases, real-world outcomes, prostate cancer registry, androgen deprivation therapy, comorbidities
MeSH terms
Adult, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Registries, Survival Rate, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. https://app.cochat.ai/papers/10.1007/s11523-020-00720-2
The paper
Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., Feyerabend, S., Matveev, V., Lefresne, F., Lukac, M., Wapenaar, R., & Costa, L. (2020). Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Targeted Oncology. https://doi.org/10.1007/s11523-020-00720-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.